Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels

Journal of Allergy and Clinical Immunology

Volumn 137, Issue 6, 2016, Pages 1822-1829.e1

  Joseph, Kusumam ^a   Tholanikunnel, Baby G ^a   Wolf, Bethany ^a   Bork, Konrad ^b   Kaplan, Allen P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

bradykinin; C1 inhibitor; Hereditary angioedema; plasminogen activator inhibitor

Indexed keywords

ALPHA 2 ANTIPLASMIN; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 12; BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; INTER ALPHA TRYPSIN INHIBITOR; KALLIKREIN; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLASMINOGEN ACTIVATOR INHIBITOR 3; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DILUTION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HEREDITARY ANGIOEDEMA WITH NORMAL C1 INHIBITOR LEVEL; HUMAN; HUMAN TISSUE; PLASMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; WESTERN BLOTTING; ANGIOEDEMAS, HEREDITARY; BLOOD; CASE CONTROL STUDY; DEFICIENCY; FEMALE; GENETICS; MALE; METABOLISM; MUTATION;

ANGIOEDEMAS, HEREDITARY; BRADYKININ; CASE-CONTROL STUDIES; COMPLEMENT C1 INHIBITOR PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XII; FEMALE; HUMANS; KALLIKREINS; MALE; MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEOLYSIS;

EID: 84942022407     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2015.07.041     Document Type: Article

References (41)

1. K. Bork, S.E. Barnsterdt, P. Koch, and H. Traupe Hereditary angioedema with normal C1 inhibitor activity in women Lancet 356 2000 213 217
2. K.E. Binkley, and A. Davis 3rd Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema J Allergy Clin Immunol 106 2000 546 550
3. G. Dewald, and K. Bork Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor Biochem Biophys Res Commun 343 2006 1286 1289
4. K. Bork, K. Wulff, J. Hardt, G. Witzke, and P. Staubach Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy J Allergy Clin Immunol 124 2009 129 134
5. S. Cichon, L. Martin, H.C. Hennies, F. Müller, K. Van Driessche, A. Karpushova, and et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III Am J Hum Genet 79 2006 1098 1104
6. K. Bork, R. Kleist, J. Hardt, and G. Witzke Kallikrein-kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr 309 lys Blood Coagul Fibrinolysis 20 2009 325 332
7. K. Bork, D. Gul, J. Hardt, and G. Dewald Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course Am J Med 120 2007 987 992
8. L. Bouillet, I. Boccon-Gibod, D. Ponard, C. Drouet, J.Y. Cesbron, C. Dumestre-Perard, and et al. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks [letter] Ann Allergy Asthma Immunol 103 2009 448
9. J.A. Cronin, and K.M. Maples Treatment of an attack of type III hereditary angioedema with ecallantide [letter] Ann Allergy Asthma Immunol 108 2012 61 62
10. B.L. Zuraw Clinical practice. Hereditary angioedema N Engl J Med 359 2008 1027 1036
11. K. Joseph, S. Bains, B.G. Tholanikunnel, A. Bygum, A. Aabom, C. Koch, and et al. A novel assay to diagnose hereditary angioedema utilizing inhibition of bradykinin-forming enzymes Allergy 70 2015 115 119
12. K. Joseph, B.G. Tholanikunnel, A. Bygum, B. Ghebrehiwet, and A.P. Kaplan Factor XII independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II J Allergy Clin Immunol 132 2013 470 475
13. K. Joseph, T. Tholanikunnel, and A.P. Kaplan Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis Ann Allergy Asthma Immunol 104 2010 50 54
14. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 1970 680 685
15. 2-macroglobulin-kallikrein complexes J Biol Chem 260 1985 4257 4263
16. D. Collen Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma Eur J Biochem 69 1976 209 216
17. 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway Blood 66 1985 1086 1091
18. F. Espana, M. Berrettini, and J.H. Griffin Purification and characterization of plasma protein C inhibitor Thromb Res 55 1989 369 384
19. B. Malde, J. Regalado, and P.A. Greenberger Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers Ann Allergy Asthma Immunol 98 2007 57 63
20. K. Joseph, B.G. Tholanikunnel, and A.P. Kaplan Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of Factor XII Proc Natl Acad Sci U S A 99 2002 896 900
21. C.G. Cochrane, S.D. Revak, and K.D. Wuepper Activation of Hageman factor in solid and fluid phases: a critical role of kallikrein J Exp Med 138 1973 1564 1583
22. J.T. Dunn, M. Silverberg, and A.P. Kaplan The cleavage and formation of activated Hageman factor by autodigestion and by kallikrein J Biol Chem 257 1982 1779 1784
23. E.G. Levin, and D.J. Loskutoff Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators J Cell Biol 94 1982 631 636
24. K. Bork, K. Braddin, N. Heinburger, E. Lindhoff, G. Mosch, and G. Witzke Reduced PAI-1 activities in patients with angioedema (AE) due to C1 inhibitor deficiency [abstract] Thromb Haemost 65 1991 1271
25. M. Van Geffen, M. Cugno, P. Lap, A. Loof, M. Cicardi, and W. van Heerde Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency Clin Exp Immunol 167 2011 472 478
26. R. Mehta, and A.D. Shapiro Plasminogen activator inhibitor type I deficiency Hemophilia 14 2008 1255 1260
27. K. Bork, K. Wulff, P. Meinke, N. Wagner, J. Hardt, and G. Witzke A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor Clin Immunol 141 2011 31 35
28. K. Bork, K. Wulff, J. Hardt, G. Witzke, and P. Lohse Characterization of a partial exon 9/intron 9 deletion in the coagulation factor XII gene (F12) detected in two Turkish families with hereditary angioedema and normal C1 inhibitor Hemophilia 20 2014 e372 e375
29. N. Kiss, E. Barabas, A. Halasz, A.L. Varga, Z. Prohanska, and A. Szilagyi Novel duplication in the F12 gene in a patient with recurrent angioedema Clin Immunol 149 2013 142 145
30. M. Silverberg, J.T. Dunn, L. Gaven, and A.P. Kaplan Autoactivation of human Hageman factor: demonstration utilizing a synthetic substrate J Biol Chem 255 1990 7281 7286
31. A.S. Weiss, J.I. Gallin, and A.P. Kaplan Fletcher factor deficiency: a diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation J Clin Invest 53 1974 622 633
32. D.L. Tankersley, and J.S. Finlaysen Kinetics of activation and autoactivation of human factor XII Biochemistry 23 1984 273 279
33. J. Björkqvist, S. de Maat, U. Lewandrowski, A. Di Gennaro, C. Oschatz, K. Schönig, and et al. Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III J Clin Invest 125 2015 3132 3146
34. B.L. Zuraw, K. Bork, K.E. Binkley, A. Banerji, S.C. Christiansen, A. Castaldo, and et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel Allergy Asthma Proc 33 suppl 2012 S145 S156
35. E.K. Kruithof, C. Tran-Thang, A. Gudinchet, J. Hauert, G. Nicoloso, C. Genton, and et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors Blood 69 1987 460 466
36. E.K. Kruithof, A. Gudinchet, and F. Bachmann Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states Thromb Haemost 59 1988 7 12
37. A.P. Kaplan, and K.F. Austen The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator J Exp Med 136 1972 1378 1393
38. K. Joseph, and A.P. Kaplan Formation of Bradykinin: a major contributor to the innate inflammatory response Adv Immunol 86 2005 159 208
39. L.A. Miles, J.S. Greengard, and J.H. Griffin A comparison of the abilities of plasma kallikrein, β-factor XIIa, factor XI and urokinase to activate plasminogen Thromb Res 28 1983 407 417
40. D. Smith, M. Gilbert, and W.G. Owen Tissue plasminogen activator release in vitro in response to vasoactive agents Blood 66 1985 835 839
41. N.J. Brown, J.H. Nadean, and D.E. Vaughan Selective stimulation of tissue-type plasminogen activator (tPA) in vivo by infusion of bradykinin Thromb Haemost 77 1997 522 525